Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 20/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | FABP1 | P07148 | 1/20 | 1.00 |
| ▸ | THRB | P10828 | 1/20 | 1.00 |
| ▸ | LIFR | P42702 | 1/20 | 1.00 |
| ▸ | RECQL | P46063 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | HSD17B13 | Q7Z5P4 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29354246 | 1.00 | NR1H4 (1.00) | NR1H4MEN1FABP1THRBLIFR | |
| SCHEMBL29459634 | 1.00 | NR1H4 (1.00) | NR1H4MEN1FABP1THRBLIFR | |
| SCHEMBL3996237 | 1.00 | NR1H4 (1.00) | NR1H4MEN1FABP1THRBLIFR | |
| SCHEMBL14601398 | 0.95 | NR1H4 (0.91) | NR1H4MEN1FABP1THRBLIFR | |
| SCHEMBL2491489 | 0.92 | NR1H4 (0.85) | NR1H4MEN1FABP1THRBLIFR | |
| SCHEMBL2491490 | 0.92 | NR1H4 (0.85) | NR1H4MEN1FABP1THRBLIFR | |
| SCHEMBL12932245 | 0.90 | NR1H4 (0.81) | NR1H4MEN1FABP1THRBLIFR | |
| SCHEMBL5354375 | 0.89 | NR1H4 (1.00) | NR1H4MEN1FABP1THRBLIFR | |
| SCHEMBL16448984 | 0.88 | NR1H4 (0.91) | NR1H4MEN1FABP1THRBLIFR | |
| SCHEMBL13805380 | 0.88 | NR1H4 (0.79) | NR1H4MEN1FABP1THRBLIFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 200 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260108482-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | ESCIENT PHARMACEUTICALS INC (US) | 2026-04-23 | — | — | US | claimed |
| EP-4171600-B1 | PHARMACEUTICAL COMPOSITION COMPRISING A COMBINATION OF A GUANYLATE CYCLASE C (GUCY2C) AGONIST AND A SHORT-CHAIN FATTY ACID OR PRODRUG THEREOF | OCVIRK SOEREN (DE) | 2024-11-27 | — | — | EP | claimed |
| US-20240300907-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | INCYTE CORPORATION | 2024-09-12 | — | — | US | claimed |
| US-12083185-B2 | Small polymeric carriers for delivery of agents | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2024-09-10 | — | — | US | claimed |
| EP-4376865-A2 | PULSE PROTEIN-BASED COMPOSITION FOR ACTIVATING THE SYNTHESIS OF FGF19 | ROQUETTE FRERES (FR) | 2024-06-05 | — | — | EP | claimed |
| US-11840521-B2 | Modulators of Mas-related G-protein receptor X4 and related products and methods | ESCIENT PHARMACEUTICALS, INC. (US) | 2023-12-12 | — | — | US | claimed |
| US-20230226143-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A COMBINATION OF A GUANYLATE CYCLASE C (GUCY2C) AGONIST AND A SHORT-CHAIN FATTY ACID OR PRODRUG THEREOF | OCVIRK SOREN (DE) | 2023-07-20 | — | — | US | claimed |
| US-20230159474-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | INCYTE CORPORATION | 2023-05-25 | — | — | US | claimed |
| EP-4171600-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A COMBINATION OF A GUANYLATE CYCLASE C (GUCY2C) AGONIST AND A SHORT-CHAIN FATTY ACID OR PRODRUG THEREOF | OCVIRK, Sören (DE) | 2023-05-03 | — | — | EP | claimed |
| US-20230053860-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | INCYTE CORPORATION | 2023-02-23 | — | — | US | claimed |
| WO-2022002369-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A COMBINATION OF A GUANYLATE CYCLASE C (GUCY2C) AGONIST AND A SHORT-CHAIN FATTY ACID OR PRODRUG THEREOF | OCVIRK SOEREN (DE) | 2022-01-06 | — | — | WO | claimed |
| US-20210330808-A1 | SMALL POLYMERIC CARRIERS FOR DELIVERY OF AGENTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-10-28 | — | — | US | claimed |
| WO-2021211839-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | ESCIENT PHARMACEUTICALS, INC. (US) | 2021-10-21 | — | — | WO | claimed |
| EP-3863609-A1 | SMALL POLYMERIC CARRIERS FOR DELIVERY OF AGENTS | University of Pittsburgh - Of the Commonwealth System of Higher Education (US) | 2021-08-18 | — | — | EP | claimed |
| EP-3777863-A1 | CENICRIVIROC COMBINATION THERAPY FOR THE TREATMENT OF FIBROSIS | Tobira Therapeutics, Inc. (US) | 2021-02-17 | — | — | EP | claimed |
| US-20210032213-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | INCYTE CORPORATION | 2021-02-04 | — | — | US | claimed |
| US-20200165608-A1 | INHIBITION OF VASCULAR ENDOTHELIAL CELL-MEDIATED PHAGOCYTIC PROCESSES FOR TREATMENT OF DEMYELINATING CONDITIONS | NATIONAL SCIENCE FOUNDATION | 2020-05-28 | — | — | US | claimed |
| US-20170319548-A1 | CENICRIVIROC COMBINATION THERAPY FOR THE TREATMENT OF FIBROSIS | TOBIRA THERAPEUTICS, INC. (US) | 2017-11-09 | — | — | US | claimed |
| EP-3191100-A1 | CENICRIVIROC COMBINATION THERAPY FOR THE TREATMENT OF FIBROSIS | Tobira Therapeutics, Inc. (US) | 2017-07-19 | — | — | EP | claimed |
| WO-2016040860-A1 | CENICRIVIROC COMBINATION THERAPY FOR THE TREATMENT OF FIBROSIS | TOBIRA THERAPEUTICS, INC. (US) | 2016-03-17 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226143-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A COMBINATION OF A GUANYLATE CYCLASE C (GUCY2C) AGONIST AND A SHORT-CHAIN FATTY ACID OR PRODRUG THEREOF | GUCY1B2, GUCY1A2, GUCY1A1 | NR1H4 222/4885MEN1 2903/4885FABP1 585/4885 |
| US-11840521-B2 | Modulators of Mas-related G-protein receptor X4 and related products and methods | MRGPRX4, MRGPRX1, MRGPRX2 | NR1H4 187/4885MEN1 524/4885FABP1 1814/4885 |
| US-20170319548-A1 | CENICRIVIROC COMBINATION THERAPY FOR THE TREATMENT OF FIBROSIS | CCR2, CCR5, CCR1 | NR1H4 19/4885MEN1 4708/4885FABP1 31/4885 |
| US-20210032213-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | MRGPRX4, MRGPRX1, MRGPRX2 | NR1H4 189/4885MEN1 546/4885FABP1 1807/4885 |
| US-20260108482-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | MRGPRX4, MRGPRX1, MRGPRX2 | NR1H4 80/4885MEN1 962/4885FABP1 1580/4885 |
| US-12083185-B2 | Small polymeric carriers for delivery of agents | CD44, PGF, SLC46A1 | NR1H4 1214/4885MEN1 3422/4885FABP1 526/4885 |
| US-20230159474-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | MRGPRX4, MRGPRX1, MRGPRX2 | NR1H4 187/4885MEN1 524/4885FABP1 1814/4885 |
| US-20240300907-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | MRGPRX4, MRGPRX1, MRGPRX2 | NR1H4 187/4885MEN1 524/4885FABP1 1814/4885 |
| US-20230053860-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | MRGPRX4, MRGPRX1, MRGPRX2 | NR1H4 187/4885MEN1 524/4885FABP1 1814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.